Resalis Therapeutics appoints medical director

Resalis Therapeutics SRL, a biotechnology company developing microRNA-targeted therapies, has appointed Sandor Batkai as medical director. Dr Batkai has over 20 years’ experience in cardiovascular, metabolic and RNA therapeutics research and early development, and was most recently co-founder and head of medical research and intelligence at Cardior Pharmaceuticals. At Resalis, he will be responsible for the strategy, design and operational execution of the company’s lead candidate, RES-010, an antisense oligonucleotide targeting miR-22 to treat obesity. The drug is being evaluated in a Phase 1 clinical trial. Dr Batkai was a group leader at the Hannover Medical School, Germany, and has an MD from Heidelberg University, Germany, and Semmelweis University, Hungary.

Resalis Therapeutics announced the appointment on 22 January 2026.